MEDULLARY THYROID CANCER
Clinical trials for MEDULLARY THYROID CANCER explained in plain language.
Never miss a new study
Get alerted when new MEDULLARY THYROID CANCER trials appear
Sign up with your email to follow new studies for MEDULLARY THYROID CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a simple shot replace IV drips for some cancer patients?
Disease control OngoingThis early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New pill targets rare cancer drivers in chinese patients
Disease control OngoingThis phase 2 study tests an oral drug called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with specific RET gene changes. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the pill daily, and d…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New pill shows promise against Hard-to-Treat RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug shows promise for Hard-to-Treat thyroid cancer
Disease control OngoingThis study tests whether the drug selpercatinib works better than current standard treatments for people with a specific type of advanced thyroid cancer (medullary thyroid cancer with a RET gene mutation). About 291 adults (and some teens) whose cancer has spread or can't be remo…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New oral drug shows promise for kids with rare RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New pill targets Hard-to-Treat cancers after other drugs fail
Disease control OngoingThis early-stage trial is testing an oral drug called LOXO-260 in about 70 people with advanced cancers that have a specific change in the RET gene. The cancers have stopped responding to other targeted treatments. The study aims to find the safest dose and see if the drug can sh…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 26, 2026 14:08 UTC
-
Lower drug dose may offer same benefit with fewer side effects for thyroid cancer patients
Disease control OngoingThis study tests whether a lower dose (60 mg) of the drug cabozantinib works as well as the standard higher dose (140 mg) in people with progressive, metastatic medullary thyroid cancer. The goal is to see if the lower dose can control cancer growth for a similar length of time w…
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE4 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 26, 2026 12:52 UTC
-
Which scan spots hidden tumors best? new study aims to find out
Diagnosis OngoingThis study compares three different PET/CT scans (68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG) in 50 people with metastatic neuroendocrine tumors. The goal is to see if all tumors show up on the standard scan or if some are missed, which could change treatment. Participants will get …
Matched conditions: MEDULLARY THYROID CANCER
Phase: PHASE2 • Sponsor: University of Alberta • Aim: Diagnosis
Last updated Jun 27, 2026 07:58 UTC